ERBB2 and neoplasm: According to molecular classification of breast tumours, the most common was luminal B tumour with 61 patients (32.3%) followed by HER2 + with 59 patients (31.2%), triple-negative with 55 patients (29.1%), and luminal A with 14 patients (7.4%).